Start-Up Quarterly Statistics, Q4 2015
This article was originally published in Start Up
Start-ups raised $2.41 billion in Q4 2015. Biopharma companies penned 29 alliances; seven acquisitions were signed in the biopharma and diagnostics industries.
You may also be interested in...
Our 12th annual analysis reveals both an expansion of historical patterns of Series A financings and the emergence of a new group of heavily committed, relatively short-term investors.
Christopher Viebacher's new venture Boston Pharmaceuticals was established with enough capital - $600 million - to scour thousands of Phase-I ready programs and build a portfolio of 20 to 25 early-stage drug candidates that it will attempt to de-risk then sell or license to interested partners
During Q2, biopharma merger and acquisition value reached $25.4bn and drew in $27.3bn in potential deal value from alliances. Device company M&A values reached $2.7bn, while in vitro diagnostic firms and research tools players completed M&A activity that totaled $534.3m.